Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer

BACKGROUND: First-line treatment with FOLFOXIRI plus bevacizumab (BEV) is highly effective and regarded as one of the standards-of-care for patients with metastatic colorectal cancer (mCRC), despite the high incidence of neutropenia and diarrhea as side effects. AXEPT, an Asian phase III study, show...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyo, Masaaki, Kato, Takeshi, Yoshino, Takayuki, Yamanaka, Takeharu, Bando, Hideaki, Satake, Hironaga, Yamazaki, Kentaro, Taniguchi, Hiroya, Oki, Eiji, Kotaka, Masahito, Oba, Koji, Miyata, Yoshinori, Muro, Kei, Komatsu, Yoshito, Baba, Hideo, Tsuji, Akihito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7376863/
https://www.ncbi.nlm.nih.gov/pubmed/32703200
http://dx.doi.org/10.1186/s12885-020-07186-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7376863/
https://www.ncbi.nlm.nih.gov/pubmed/32703200
http://dx.doi.org/10.1186/s12885-020-07186-5

Ejemplares similares